Adagio Therapeutics

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adagio Therapeutics Inc (NASDAQ: ADGI) is soaring on abnormally-high volume Thursday as traders discuss the stock on various social media platforms. Adagio Therapeutics' average session volume is about 29 million, according to data from Benzinga Pro.

What's Going On With Adagio Therapeutics Stock Today?

You can always count on investment bank analysts to yell fire after a biotech's lead program goes up in flames.

Why Adagio Therapeutics Stock Is Falling Again Today

Doximity

Digital World Acquisition Corp

Roblox

ZIM Integrated Shipping Services

Digital World Acquisition, ZIM Integrated Shipping Services, Adagio Therapeutics, Roblox, and Doximity saw the largest percentage increase in stock price since initial listing.

Top 5 IPOs of 2021

Shares of ADGI stock are down more than 75% after new data showed its ADG-20 lacked effectiveness against the omicron variant. The post ADGI Stock Alert: The Omicron Variant Just Sent Adagio Therapeutics Plunging appeared first on InvestorPlace.

ADGI Stock Alert: The Omicron Variant Just Sent Adagio Therapeutics Plunging

Adagio Therapeutics Inc (NASDAQ: ADGI) shares are plunging during the premarket session after issuing an update following external in vitro analyses to evaluate the neutralizing activity of ADG20 against the omicron variant.  The in vitro data generated through both authentic and pseudovirus testing of the omicron variant shows a greater than 300-fold reduction in neutralizing activity of ADG20 against omicron.

Why Are Adagio Shares Plunging Today?

The company's lead candidate appears to be ineffective against the omicron variant.

Why Adagio Therapeutics Stock Is Crashing Today

Editas Medicine

SPDR S&P Biotech ETF

All three of these biotech stocks lost around half their value over the past few months.

3 Beaten-Down Biotech Stocks -- Are They Bargains Now?

Will Adagio's COVID Antibody Therapy Be Too Late to the Party?

On Tuesday, Adagio Therapeutics Inc. (NASDAQ:ADGI) shares skyrocketed by more than 35% before declining for a mid-day net gain of about 4.5%. The rally was fueled by social media chatter, which saw trading volume surpass 10 million for the second consecutive day.

Adagio Therapeutics stock outlook as shares spike 35% on social media chatter

"ADG20 was uniquely designed to combine breadth, potency and duration of protection against SARS-CoV-2 for up to one year in a single injection."

Adagio Therapeutics extends 3-day gain to 319% on hopes that its antiviral can treat the Omicron variant

Adagio Therapeutics (ADGI) stock is rising higher on Tuesday as investors on social media can't stop talking about the company. The post ADGI Stock: The Social Media Chatter That Has Adagio Therapeutics Soaring Today appeared first on InvestorPlace.

ADGI Stock: The Social Media Chatter That Has Adagio Therapeutics Soaring Today

Adagio Therapeutics Inc (NASDAQ: ADGI) was up more than 75% on Monday after the biotech firm said Omicron was unlikely to be more resistant against its investigational monoclonal antibody, ADG20, despite a record number of mutations. Morgan Stanley raised its price target on ADGI The stock further got a boost as Morgan Stanley upgraded it […] The post Morgan Stanley: Omicron will benefit this relatively new biotech firm appeared first on Invezz.

Morgan Stanley: Omicron will benefit this relatively new biotech firm

NRX Pharmaceuticals

Valneva SE

Vir Biotechnology

With all eyes on the pandemic once again, these biotech players could be gaining more exposure.

4 Top Biotech Stocks To Watch Now

Shares of ADGI stock are soaring higher by 80% after the company stated that its ADG-20 antibody is effective against the omicron variant. The post ADGI Stock Soars as Analysts Lock On to Its Omicron-Fighting Potential appeared first on InvestorPlace.

ADGI Stock Soars as Analysts Lock On to Its Omicron-Fighting Potential

Merck

Pfizer

The news of a new variant of the coronavirus Friday sent financial markets into a tailspin. The adversity could present an opportunity for a handful of biopharma stocks, according to a Morgan Stanley analyst.

3 Pharma Stocks Morgan Stanley Says Will Be Omicron Variant Beneficiaries

The stock price of Adagio Therapeutics Inc (NASDAQ: ADGI) increased by over 25% pre-market today. This is why it happened.

Adagio Therapeutics (ADGI) Stock: Why The Price Surged Today

Additional in vitro studies to determine neutralization activity of ADG20 against Omicron are ongoing

Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro

WALTHAM, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that Jill Andersen has been appointed as chief legal officer, bringing over 20 years of legal, compliance and leadership experience in the pharmaceutical industry, government and private practice. In addition, Redonda Miller, M.D., MBA, president of The Johns Hopkins Hospital, and Ellen Marram, an experienced corporate director and board leader, and the former CEO of several consumer product companies, have joined Adagio's board of directors.

Adagio Therapeutics Announces Expansion of Management Team and Board of Directors to Support Rapid Advancement and Commercial Readiness of ADG20 for COVID-19

FDA Feedback Supports Planned Emergency Use Authorization (EUA) Submission for ADG20 for Prevention of COVID-19; Interim Clinical Data Package from EVADE Prevention Trial to Support EUA Submission Expected in Second Quarter 2022

Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results

Adagio Therapeutics Inc (NASDAQ: ADGI) has announced new in vitro data demonstrating retained neutralizing activity of ADG20 against a diverse panel of circulating SARS-CoV-2 variants, including the newly emerged Lambda and Mu variants. Related:   Adagio's COVID-19 Candidate Shows Prolonged Half-Life, Neutralization At Six Months.

Adagio Stock Jumps On Additional Preclinical Data For Its COVID-19 Antibody

Data to be presented at the 2021 ISIRV-WHO Virtual Conference Data to be presented at the 2021 ISIRV-WHO Virtual Conference

Adagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Known SARS-CoV-2 Variants

Adagio Therapeutics Inc (NASDAQ: ADGI) has announced new data from its COVID-19 antibody program.  Related Link:   Adagio Therapeutics To Expand Late-Stage COVID-19 Antibody Trial.

Adagio's COVID-19 Candidate Shows Prolonged Half-Life, Neutralization At Six Months

WALTHAM, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that management will participate in a fireside chat during the Guggenheim 2nd Annual Vaccines & Infectious Day Conference on Wednesday, Oct. 6, 2021 at 1:30 p.m. ET.

Adagio Therapeutics to Participate in the Guggenheim 2nd Annual Vaccines & Infectious Day Conference

ADG20 Continues to be Well Tolerated in Healthy Volunteers with Prolonged Half-Life and Serum Virus Neutralization Activity Observed out to Six Months in Ongoing Phase 1 Study

Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19

New Data Supporting Potential of ADG20 for Both the Treatment and Prevention of COVID-19 to be Presented at IDWeek 2021

News for Adagio Therapeutics Stock (ADGI)